Navigation Links
Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
Date:11/13/2008

SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Needham & Company, LLC's Focus on Infectious Disease Conference on Thursday, November 20, 2008 at 10:00 a.m. EST (7:00 a.m. PST) at the Needham and Company, LLC's office in New York City.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will present an overview of Anadys and its three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through December 4, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development pro
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- An analysis by Replikins, Ltd. of Pubmed data ... virus strains has revealed extensive conservation and sharing ... and sharing of specific Replikin gene structures has permitted ... it did for the H5N1 influenza vaccine and the ... found to be effective (1,2). This ...
(Date:8/26/2014)... Israel , August 26, 2014 ... 3DM, supports NHS hospitals with surgery validation using its Stratasys ... - Performing surgery on 3D printed models prior to ... and provides an effective aid for both patient and surgeon ... SSYS ), a global leader of 3D printing and ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... is becoming more and more a rare option rather than ... still getting feedback about people giving two-weeks' notice and then ... notices no longer are part of the standard practice. , ... , ,One reader said you should give a two-week notice ...
... leaves behind an economic year in which some new investments ... tech economy positioned itself to prosper in some emerging sectors. ... investment climate must remain warm and state policymakers need to ... ability to compete in the global marketplace. What's in store ...
... Dow Jones Industrials had a fabulous year and outperformed ... very solid year, by a large margin. The two key ... because the different composition of each. , ,The NASDAQ Biotech ... greater spectrum of the biotech industry (larger and smaller companies), ...
Cached Biology Technology:Two-week notices: People are still concerned 2Two-week notices: People are still concerned 3Two-week notices: People are still concerned 4Two-week notices: People are still concerned 5Wisconsin's high-growth economy: '07 predictions 2Wisconsin's high-growth economy: '07 predictions 3Wisconsin's high-growth economy: '07 predictions 42006: A mixed blessing for Midwest life science companies 22006: A mixed blessing for Midwest life science companies 32006: A mixed blessing for Midwest life science companies 42006: A mixed blessing for Midwest life science companies 52006: A mixed blessing for Midwest life science companies 62006: A mixed blessing for Midwest life science companies 72006: A mixed blessing for Midwest life science companies 82006: A mixed blessing for Midwest life science companies 92006: A mixed blessing for Midwest life science companies 102006: A mixed blessing for Midwest life science companies 11
(Date:8/26/2014)... a protective tent over a colony of harmful ... especially difficult. Microorganisms protected in a biofilm pose ... resistance and recalcitrance to treatment, and biofilm-protected bacteria ... infections in humans and are 50 to 1,000 ... infections. , "In essence, we may have stumbled ...
(Date:8/26/2014)... Illinois engineers are bringing a touch of color ... new continuous glucose monitoring material that changes color ... is so precise that doctors and patients may ... dosing - something not possible using current ... significant limitations to current continuous glucose monitoring technologies," ...
(Date:8/26/2014)... and optical microresonators, researchers at the University of ... amplifier (or laser) design, paving the way for ... systems at the microscopic scale that amplify light ... Eden, a professor of electrical and computer engineering ... well-suited for routing optical power on a chip ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3A glucose meter of a different color provides continuous monitoring 2A glucose meter of a different color provides continuous monitoring 3Symphony of nanoplasmonic and optical resonators produces laser-like light emission 2
... more than 180 research papers suggests fish oils could minimise ... a review by researchers at the University of Liverpool has ... and Chronic Disease reviewed research from around the world to ... omega-3s had a role to play in aiding weight loss. ...
... complex, weight-bearing hips of walking animals from the basic hips ... Tetrapods, or four-legged animals, first stepped onto land about ... by strong hipbones and a connection through the spine via ... fish ancestors of tetrapods. In a study published ...
... Biotechnology (DBT) and Bharat Biotech announced positive results from ... developed and manufactured in India. Data from the trial, ... for IndiaThe Evidence and the Promise, showed ROTAVAC to ... The clinical study demonstrates for the first time that ...
Cached Biology News:Fish oil may stall effects of junk food on brain 2From ocean to land: The fishy origins of our hips 2Rotavirus vaccine developed in India demonstrates strong efficacy 2Rotavirus vaccine developed in India demonstrates strong efficacy 3Rotavirus vaccine developed in India demonstrates strong efficacy 4
... Have you bought a Perkin Elmer UltraVIEW system ... the Andor iXon and iQ software? No problem. ... upgrade. You keep your existing microscope, lasers, Sutter ... customise it to work with our precision controller ...
...
... is a 96-well ELISA-compatible plate (containing 12 x ... Monoclonal Antibody is immobilized by a method that ... the tail fiber protein of the T7 bacteriophage. ... 10 9 phage per well and low ...
... The TRAPeze RT Telomerase Detection ... in vitro assay for the ... quantification of telomerase activity. It ... TRAPeze assay and adds the ...
Biology Products: